A UK-based KOL discusses the treatment pathway of triple-negative breast cancer with emphasis on the differences in treating de novo and relapsed metastatic disease. The KOL also highlights the difficulties surrounding the use of immunotherapy and the unmet clinical need for novel therapeutic approaches, as well as the push for widespread genomic testing in the UK. 

This interview was conducted on Aug. 1, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.